‘Revolutionary’ lung cancer drug made available on NHS in England

Patients in England first to benefit from Sotorasib after drug proven to halt growth of tumours for seven months

Lung cancer patients in England will become the first in Europe to benefit from a revolutionary" new drug that can halt the growth of tumours by targeting the so-called Death Star" mutation.

The medication, Sotorasib, will be fast-tracked to NHS patients after it was proven in clinical trials to stop lung cancer growing for seven months.